Home » Stocks » VIRX

Viracta Therapeutics, Inc. (VIRX)

Stock Price: $8.04 USD 0.27 (3.47%)
Updated Apr 21, 2021 4:00 PM EDT - Market closed
After-hours: $8.18 +0.14 (1.74%) Apr 21, 7:07 PM
Market Cap 297.44M
Revenue (ttm) 120,000
Net Income (ttm) -21.61M
Shares Out 4.03M
EPS (ttm) -5.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 21
Last Price $8.04
Previous Close $7.77
Change ($) 0.27
Change (%) 3.47%
Day's Open 7.70
Day's Range 7.45 - 8.28
Day's Volume 329,408
52-Week Range 1.12 - 18.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company managemen...

1 week ago - PRNewsWire

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biophar...

Other stocks mentioned: PRAH, PSTX, SLRX, SNSS
1 month ago - Benzinga

An analyst upgrade is the near-term catalyst, but for Sunesis Pharmaceuticals, it's really about patents in oncology and an impending merger with Viracta. The post SNSS Stock: Why Sunesis Pharmaceutical...

Other stocks mentioned: SNSS
1 month ago - InvestorPlace

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmace...

Other stocks mentioned: SNSS
3 months ago - Business Wire

NEW YORK, Dec. 4, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City...

Other stocks mentioned: SNSS
4 months ago - PRNewsWire

WILMINGTON, Del., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Sunesis Pharmaceuticals, Inc. (“Sunesis”) (NASDAQ CM: SNSS) regarding possible breaches of f...

Other stocks mentioned: SNSS
4 months ago - GlobeNewsWire

Investors need to pay close attention to Sunesis Pharmaceuticals (SNSS) stock based on the movements in the options market lately.

Other stocks mentioned: SNSS
4 months ago - Zacks Investment Research

NEW YORK, Nov. 30, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sunesis Pharmaceuticals, Inc. ("Sunesis...

Other stocks mentioned: SNSS
4 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) and Viracta Therapeutics, Inc. is fair...

Other stocks mentioned: SNSS
4 months ago - Business Wire

Shares of SNSS stock are climbing higher on Monday after Sunesis Pharmaceuticals announced a merger deal with Viracta Therapeutics. The post Sunesis Pharmaceuticals News: 7 Things for SNSS Stock Investo...

Other stocks mentioned: SNSS
4 months ago - InvestorPlace

Merger to c reate Nasdaq-listed company focused on developing Viracta's precision oncology pipeline targeting virus-associated malignancies

Other stocks mentioned: SNSS
4 months ago - GlobeNewsWire

Sunesis to Host Conference Call Today at 4:30 PM Eastern Time Sunesis to Host Conference Call Today at 4:30 PM Eastern Time

Other stocks mentioned: SNSS
5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 16th, 2020 at 4:30pm E...

Other stocks mentioned: SNSS
5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular Target...

Other stocks mentioned: SNSS
6 months ago - GlobeNewsWire

The drugmaker is having to take a last-resort measure to keep its shares listed on the Nasdaq stock exchange.

Other stocks mentioned: SNSS
7 months ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences.

Other stocks mentioned: SNSS
7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Ce...

Other stocks mentioned: SNSS
7 months ago - GlobeNewsWire

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) were down 4.45% in after-market trading after the company reported Q2 results.

Other stocks mentioned: SNSS
8 months ago - Benzinga

Sunesis (SNSS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: SNSS
8 months ago - Zacks Investment Research

Sunesis Pharmaceuticals (NASDAQ: SNSS) will be releasing its next round of earnings this Tuesday, August 11.

Other stocks mentioned: SNSS
8 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30 p....

Other stocks mentioned: SNSS
8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its c...

Other stocks mentioned: SNSS
8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it intends to offer and sell, subject to market and other conditions, s...

Other stocks mentioned: SNSS
8 months ago - GlobeNewsWire

Is (SNSS) Outperforming Other Medical Stocks This Year?

Other stocks mentioned: SNSS
8 months ago - Zacks Investment Research

Company reduces workforce to focus on development of PDK1 inhibitor, SNS-510 Company reduces workforce to focus on development of PDK1 inhibitor, SNS-510

Other stocks mentioned: SNSS
9 months ago - GlobeNewsWire

Company Shifting Resources from Vecabrutinib to Development of PDK-1 Inhibitor SNS-510 Company Shifting Resources from Vecabrutinib to Development of PDK-1 Inhibitor SNS-510

Other stocks mentioned: SNSS
9 months ago - GlobeNewsWire

Is (SNSS) Outperforming Other Medical Stocks This Year?

Other stocks mentioned: SNSS
1 year ago - Zacks Investment Research

Poster to be Presented at Upcoming ASH Annual Meeting Poster to be Presented at Upcoming ASH Annual Meeting

Other stocks mentioned: SNSS
1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Financ...

Other stocks mentioned: SNSS
1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 2019 AACR-NCI-EORTC International Conference on...

Other stocks mentioned: SNSS
1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of Dire...

Other stocks mentioned: SNSS
1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. (SNSS).

Other stocks mentioned: SNSS
1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President of Fina...

Other stocks mentioned: SNSS
1 year ago - GlobeNewsWire

Sunesis Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Other stocks mentioned: SNSS
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.

Other stocks mentioned: SNSS
1 year ago - Zacks Investment Research

Investors need to pay close attention to Sunesis (SNSS) stock based on the movements in the options market lately.

Other stocks mentioned: SNSS
1 year ago - Zacks Investment Research

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

Other stocks mentioned: SNSS
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.

Other stocks mentioned: SNSS
2 years ago - Zacks Investment Research

About VIRX

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff, California.

Industry
Biotechnology
Founded
2007
CEO
Dayton Misfeldt
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
VIRX
Full Company Profile

Financial Performance

In 2020, VIRX's revenue was $120,000, a decrease of -94.21% compared to the previous year's $2.07 million. Losses were -$21.61 million, -7.37% less than in 2019.

Financial Statements